The Effect of Dopamine on Diabetic Retinopathy
Public ClinicalTrials.gov record NCT02706977. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the use of electroretinogram (ERG) using a novel handheld system, RETeval, and evaluate contrast sensitivity testing in detecting pre-clinical retinopathy on a tablet device. Investigators also seek to assess if a medication called Sinemet™ CR can improve the electrical functions of the eye in participants with diabetes mellitus. This study will include a total of 45 participants; 30 with diabetes mellitus and 15 age-matched non-diabetic controls. Participants with diabetes mellitus and electroretinogram (ERG) delays will be randomized to a low or high dose Sinemet CR group.
Study identification
- NCT ID
- NCT02706977
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- Low Dose Sinemet CR Drug
- High Dose Sinemet CR Drug
- RETeval Electroretinogram (ERG) Testing Device
- Contrast Sensitivity Testing Other
- Visual Acuity Testing Other
Drug · Device · Other
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2015
- Primary completion
- Aug 14, 2019
- Completion
- Aug 14, 2019
- Last update posted
- Oct 8, 2019
2016 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Atlanta VA Medical Center | Atlanta | Georgia | 30033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Diabetes trials
Other public records listing Diabetes. Sorted by last update posted; newest first. Not a recommendation.
- NCT07784127: Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation Not yet recruiting
- NCT07748858: Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities Recruiting
- NCT05561595: Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma Recruiting
- NCT05912647: Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes Recruiting
- NCT07676188: Leveraging Interventions for Needs and Knowledge in Diabetes (LINKD) Not yet recruiting
- NCT07674420: Wearable Insoles for Recurrent Diabetic Ulcer Prevention Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02706977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02706977 live on ClinicalTrials.gov.